文献速递胸部肿瘤

LAURA研究患者报告结局:奥希替尼用于不可切除III期EGFR突变NSCLC根治性放化疗后

Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy.
PubMed 文献 · Eur J Cancer · 2026-04-12

LAURA研究在根治性放化疗期间/后未进展的不可切除III期EGFR突变NSCLC中显示奥希替尼较安慰剂显著改善PFS。本文报告其患者报告结局:两组EORTC关键量表确认恶化风险总体无实质差异,40周内功能/症状自基线变化极小,PRO-CTCAE耐受性相似(除稀便频率和皮肤干燥严重度外),PRO数据支持奥希替尼在该场景的应用。

要点

  • 奥希替尼组与安慰剂组关键EORTC量表确认恶化风险总体无实质差异。
  • 40周内两组关键功能与症状自基线变化极小,PRO评分得以维持。
  • PRO-CTCAE示耐受性相似,仅稀便频率与皮肤干燥严重度略有差异。

核心结论

  • 不可切除III期EGFR突变NSCLC根治性放化疗后奥希替尼治疗期间PRO评分得以维持。
  • 结合显著PFS获益与预期可控的安全性,PRO数据支持奥希替尼用于该场景。

研究设计与样本

  • LAURA研究(NCT03521154)为在根治性放化疗期间/后未进展的不可切除III期EGFR突变NSCLC中比较奥希替尼与安慰剂的随机研究。
  • 采用重复测量混合模型分析EORTC QLQ-C30/LC13自基线评分变化及确认恶化时间。
  • 使用PRO-CTCAE v1.0评估耐受性。

主要发现

  • 两组基线EORTC评分可比。
  • 关键量表确认恶化风险总体无实质差异:总体健康状况/QoL HR 1.14(95%CI 0.74-1.78);躯体功能1.06(0.65-1.71);疲乏1.23(0.85-1.80);食欲丧失1.00(0.63-1.58);呼吸困难1.30(0.91-1.86);咳嗽1.17(0.81-1.71);胸痛1.46(0.95-2.23)。
  • 40周内两组关键功能/症状自基线变化极小。
  • PRO-CTCAE示奥希替尼与安慰剂在症状频率和严重度上耐受性相似,例外为稀便(「从不」/「很少」频率 vs「从不」)和皮肤干燥(「轻度」严重度 vs「无」)。

临床怎么用

  • 该PRO数据可用于向不可切除III期EGFR突变NSCLC根治性放化疗后患者说明奥希替尼治疗期间生活质量可维持。
  • 临床可关注稀便和皮肤干燥等PRO-CTCAE差异症状并进行相应管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The LAURA study in unresectable stage III EGFR-mutated NSCLC without progression during/after chemoradiotherapy demonstrated significantly improved progression-free survival (PFS) with osimertinib versus placebo after definitive chemoradiotherapy. We report patient-reported outcomes (PROs) from LAURA. PATIENTS AND METHODS: Score changes from baseline (mixed model for repeated measures analysis) and time to confirmed deterioration in health-related quality of life (HRQoL), functioning and symptoms per EORTC QLQ-C30/LC13 questionnaires were analyzed. Tolerability was assessed using the PRO-CTCAE v1.0. RESULTS: Baseline EORTC scores were comparable between treatment arms. Risk of confirmed deterioration in key scales was generally not substantially different between arms (HR [95% CI], global health status/QoL 1.14 [0.74-1.78]; physical function 1.06 [0.65-1.71]; fatigue 1.23 [0.85-1.80]; appetite loss 1.00 [0.63-1.58]; dyspnea 1.30 [0.91-1.86]; coughing 1.17 [0.81-1.71]; pain in chest 1.46 [0.95-2.23]). Over 40 weeks, minimal changes from baseline were observed for key functioning/symptoms in both arms. PRO-CTCAE responses indicated similar tolerability of osimertinib versus placebo for symptom frequency and severity, except for loose/watery stools ("never"/"rarely" frequency vs. "never") and dry skin ("mild" severity vs. "none"). CONCLUSIONS: PRO scores were maintained during osimertinib treatment of unresectable stage III EGFR-mutated NSCLC after definitive chemoradiotherapy. Together with significant PFS benefit and expected, manageable safety, the PRO data support osimertinib treatment in this setting. TRIAL REGISTRATION NUMBER: NCT03521154.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Arriola E, Casarini I, Özgüroğlu M, et al. Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy. Eur J Cancer. 2026. PMID: 42019226. doi:10.1016/j.ejca.2026.116744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。